Recently YiChang HEC Changjiang Pharmaceutical Co., Ltd. (01558 HK) successfully obtain clinical trial approvals for Insulin Glargine Injection, Isophane Protamine Recombinant Human Insulin Injection（Premixed 30R）and Isophane Protamine Recombinant Human Insulin Injection. So far, HEC has a total of four biological products for treatment of diabetes granted with clinical trial approvals. 

According to IDF（ International Diabetes Federation）data in 2015，about 400 million adults have diabetes while 100 million are Chinese and China still ranks NO.1 in the world. With a increasing trend year by year, diabetes have ranked NO.3 as common disease,  frequently-occurring disease and noninfectious chronic disease, only second to cardiovascular disease and tumor. PICO forecasted that the size of the PRC pharmaceutical market in relation to anti-diabetes products will increase to around RMB59,400 million by 2019.The PRC has experienced a rapid growth in relation to the market for second generation insulin products (especially for Premixed 30R) and third generation insulin products (especially for insulin glargine and insulin aspart).

In particular, there are only two manufacturers of originator Sanofi-Aventis and local Gan Lee in current China market for Insulin Glargine, a best-sell product of third generation insulin. HEC Pharm is expected to be the third manufacturer of insulin glargine, and evenmore the only manufacturer of which the expiry period can be the same as originator.

Isophane Protamine Recombinant Human Insulin Injection & Isophane Protamine Recombinant Human Insulin Injection（Premixed 30R）

Isophane Protamine Recombinant Human Insulin is an intermediate acting insulin while Isophane Protamine Recombinant Human Insulin Injection(Premixed 30R) is a dual phase insulin,comprising 30% regular recombinant human insulin and 70% NPH, both of which are second generation insulin. There’s a hypoglycemic effect of dual phase with only once drug giving, which can reduce dosing frequency and improve the dosing convenience, thus Premixed 30R accounts for the largest share among second insulin products market.

Glargine insulin

An analogue to long-acting insulin produced through recombinant DNA technology,which belongs to the third generation insulin products. Since the generation of  micro-precipitation by PH change after subcutaneous injection of insulin glargine, , the insulin monomeric can sustainably slowly release which enable the hypoglycemic effect last for 24h and with a “peakless” profile. Compared to conventional human insulin medications, Glargine insulin provides a better solution as basal insulin and can be given in addition to a mealtime Insulin or (oral administration drug) in clinical.